Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2002

View Archived Issues

SkyePharma and GeneMedix to develop extended-release interferon alfa-2b

Texas Biotechnology presents mid-year update

Xenical improves weight loss and glycemic control in type 2 diabetes patients on metformin

VaxGen and Genentech revise AIDS vaccine candidate agreement

Inhibitors of ubiquitin ligases as potential new anticancer agents

Antisoma's vascular targeting agent well tolerated in phase I trials

Heat-activated drug therapy for prostate cancer enters clinical trials

U.K. introduction for Amgen's novel rheumatoid arthritis therapeutic

Buprenorphine matrix patch for chronic pain relief launched in U.K.

Biochemical profile of SM-13496, an atypical antipsychotic, characterized in vitro and in vivo

Antipsychotic effects demonstrated in patients for dopamine stabilizer OSU-6162

Preclinical profile of Lu-35-138 described at CINP congress

New data on the efficacy and safety of the antidepressant S-20098

FDA approval for Remicade for remission maintenance of Crohn's disease

Gleevec submitted in U.S. and E.U. for first-line use in CML

E.U. approval for Zenapax in pediatric renal transplantation

Schering AG acquires distribution rights for Testogel in Europe

Reolysin enters phase I/II in brain cancer

Adenylyl cyclase inhibitors and their use in congestive heart failure

Novel PPARalpha agonists in Lilly pipeline

New antibacterial carbapenems in early development at Sankyo

GSK claims tachykinin NK2/NK3 antagonists for respiratory disorders

Bombesin receptor antagonists with potential in sexual dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...